BMS-193884 and BMS-207940 Bristol-Myers Squibb

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 1057-1061

  Hulpke Wette, Martin ^a   Buchhorn, Reiner ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BMS 193884; BMS 207940; BMS 207940 20; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; SITAXSENTAN; SULFONAMIDE; TEZOSENTAN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEART FAILURE; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; MEAN RESIDENCE TIME; NAUSEA; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SINGLE DRUG DOSE; STEADY STATE; STRUCTURE ACTIVITY RELATION; THORAX PAIN; TOXICITY TESTING; VERTIGO; VISUAL DISORDER;

ANIMALS; CLINICAL TRIALS; DRUG INDUSTRY; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; OXAZOLES; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0036667141     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. 206604 Annual Report 1995 - Bristol Myers Squibb Co. Bristol Myers Squibb Co Annual Report 1995 December 31
2. 242721 Tanabe has endothelin receptor antagonist in preclinical stage. Pharma Jpn 1997 1545 15
3. 340697 The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. Saad D, Mukherjee R, Thomas PB, Iannini JP, Basler CG, Hebbar L, Oa SJ, Moreland S, Webb ML, Powell JR, Spinale FG J Am Coll Cardiol 1998 32 6 1779-1786
4. 360932 American Chemical Society 219th National Meeting (Part III) Division of Medicinal Chemistry Poster Session and General Papers, San Francisco, CA, USA. IDDB Meeting Report 2000 March 26-30
5. A receptor antagonist. Murugesan N ACS 2000 219th San Francisco MEDI 164
6. A antagonists. Murugesan N, Gu Z, Stein P, Spergel S, Mathur A, Leith L, Liu E, Zhang R, Bird E, Waldron T, Marino A, Morrison R J Med Chem 2000 43 16 3111-3117
7. 394144 Recent discovery and development of endothelin receptor antagonist. Wu C Exp Opin Ther Pat 2000 10 1653-1668
8. A selective receptor antagonist BMS-193884, in patients with heart failure. Smith W, Iteld B LeJermentel T, Thomas I, Deitchmann D, Williams SP, Reyner D, Blumental M J Am Coll Cardiol 2000 35 2 Suppl A 241
9. 421267 Actelion Tracleer testicular toxicity in rats may show class effect, FDA says. FDC Reports Pink Sheet 2001 63 34 10-11
10. 423008 Heart Failure Society of America - Fifth Scientific Meeting, Emerging Pharmacological Therapies for Chronic Heart Failure, Washington DC, USA. IDDB Meeting Report 2001 September 9-12
11. 435846 Actelion Pharmaceuticals Inc. Hambrecht & Quist 2002 January 7-10
12. 441395 Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. Kim NN, Dhir V, Azadzoi KM, Traish AM, Flaherty E, Goldstein I J Androl 2002 23 1 76-83
13. 441398 Clinical experience with endothelin receptor antagonists in chronic heart failure. Seed A, Love MP, McMurray JV Heart Failure Rev 2001 6 4 317-323
14. 441400 Endothelin A receptor antagonists in congestive heart failure: Blocking the beast while leaving the beauty untouched? Spieker LE, Noll G, Ruschitzka FT, Luscher TF Heart Failure Rev 2001 6 4 301-315
15. 441405 Endothelin-1 and right-sided heart failure in rats: Effects of an endothelin receptor antagonist on the failing right ventricle. Miyauchi T, Sato R, Sakai S, Kobayashi T, Ueno M, Kondo H, Kawano S, Goto K, Yamaguchi I J Cardiovasc Pharmacol 2000 36 Suppl S327-S330
16. 442059 Biphenylsulphonamide endothelin receptor antagonists. Part 3: Structure-activity relationship of 4′-heterocyclic biphenylsulfonamides. Murugesan N, Gu Z, Stein PD, Spergel S, Bisaha S, Liu ECK, Zhang R, Webb ML, Moreland S, Barrish JC Bioorg Med Chem Lett 2002 12 4 517-520
17. 446511 American Chemical Society - 223rd National Meeting (Part IV) - Overnight report, Orlando, FL, USA. Eyles A IDDB Meeting Report 2002 April 7-11
18. 450341 Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Adviye E Pharmacotherapy 2002 22 54-65
19. 450342 Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Black SM, Bekker JM, Johengen MJ, Parry AJ, Soifer SJ, Fineman JR Pediatr Res 2000 47 1 97-106
20. 450347 Hemodynamic data and survival in children with pulmonary hypertension. Clabby M, Canter CE, Moller JH, Bridges ND J Am Coll Cardiol 1997 30 54-55
21. 450350 Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dydra I, Bonan R, Crepeau J Am Heart J 1998 135 4 614-620
22. 450351 Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ N Engl J Med 1993 328 24 1732-1739
23. 450356 High density of endothelin binding sites in the hearts of infants and children. Giannessi D, Del Ry S, Andreassi MG, Nardini V, Pelosi G, Colombo MG, Biagini A Life Sci 1999 64 8 697-705
24. 450358 Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, Leier CV, Loh E, Nicklas JM, Lewis BE Circulation 2000 101 25
25. 450360 Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Ivy DD, Parker TA, Kinsella JP, Abman SH Pediatr Res 1998 44 2 175-180
26. 450362 Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension. Komai H, Adatia IT, Elliott MJ, De Leval MR, Haworth SG J Thorac Cardiovasc Surg 1993 106 3 473-478
27. 450363 Endothelin-A receptor antagonist prevents neonatal pulmonary hypertension in meconium aspiration in piglets. Kuo CY J Formosan Med Assoc 2001 100 6 420-423
28. 450364 Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B Clin Chem Lab Med 1999 37 4 423-428
29. 450366 Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. Nootens M, Kaufmann E, Rectoro T, Toher C, Judd D, Francis GS, Rich S J Am Coll Cardiol 1995 26 5 Suppl 1 1581-1585
30. 450367 Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Prendergast B, Newby DE, Wilson LE, Webb DJ, Mankad PS Heart 1999 82 4 505-508
31. 450369 Post-cardiopulmonary bypass pulmonary hypertension in lambs with increased pulmonary blood flow. A role of endothelin 1. Reddy VM, Hendricks Munoz KD, Rajasinghe HA, Petrossian E, Hanley FL, Fineman JR Circulation 1997 95 1054-1061
32. 450372 Bosentan therapy for pulmonary arterial hypertension. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frostj A, Roux S, Leconte I, Landzberg M, Simonneau G N Engl J Med 2002 346 12 896-903
33. 450376 Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future? Spieker LE, Noll G, Ruschitzka FT, Lscher TF Heart Failure Rev 2001 6 4 301-315
34. 450380 Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. Tsutamoto T, Wada A, Hisanaga T, Maeda K, Ohnishi M, Mabuchi N, Sawaki M, Hayashi M, Hayashi M, Fujii M, Kinoshita M J AM Coll Cardiol 1999 33 2 530-537
35. 450383 Relation of relevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW Am J Cardiol 1993 71 13 1204-1209
36. 450389 Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, Temma S, Shirakami G, Imura H, Mikawa H Circulation 1991 84 6 2280-2285
37. 450393 Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Bohm M Circulation 1999 99 16 2118-2123
38. 450524 Hypotensive effect of endothelin-1 via endothelin-B-receptor pathway on pulmonary circulation is enhanced in rats with pulmonary hypertension. Sakai S, Miyauchi T, Hara J, Goto K, Yamaguchi I J Cardiovasc Pharmacol 2000 36 Suppl 1 S95-S98
39. 450616 UPMC Presbyterian website: Cardiovascular Institute/Congestive heart failure. UPMC Presbyterian Internet Site 2002
40. 452734 Bristol-Myers Squibb. SG Cowen Securities Corporation 2002 March 08